ORIC-533

ORIC-533 is an orally active, selective CD73 inhibitor with AMP-competition. ORIC-533 restores immunosuppressed CD8+ T cell proliferation and activation, triggers significant lysis and cell death of multiple myeloma cells in the bone marrow microenvironment[1].

Product Specifications

CAS Number

[2641306-62-7]

UNSPSC

12352005

Target

CD73

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/oric-533.html

Solubility

10 mM in DMSO

Smiles

O[C@H]1[C@@H](O)[C@H](N2C3=NC(Cl)=NC(NC4CCCC4)=C3C=N2)O[C@@H]1CO[C@](P(O)(O)=O)(CO)COCC5=NN=NN5

Molecular Formula

C20H29ClN9O9P

Molecular Weight

605.93

References & Citations

[1]Junttila M R, et al., ORIC-533, a small molecule CD73 inhibitor with best-in-class properties, reversesimmunosuppression and has potential as an immunomodulatory therapy in patients with multiple myeloma[J]. Cancer Research, 2022, 82 (12_Supplement) : 2074-2074.